Skip to main content
Caplight Logo









Shanghai Kangchen Bioengineering Co., Ltd.

Shanghai Kangchen Bioengineering Co., Ltd.

Private
ShanghaiHealthcare & Life Scienceshttps://www.aksomics.com/

Last Round

Series C

Extension

Jan 1, 2023

Total Funding Raised

$30.91M

Company Overview

Shanghai Kangchen Bioengineering Co., Ltd. (doing business as Aksomics) is a biotechnology company that provides technical services for life science research, including microarray analysis, sequencing, and proteomics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Biotech Equipment

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Non-AI

Keywords

epitranscriptomicsnon-coding RNAepigenomicsnext-generation sequencingNGSsingle-cell sequencingproteomicsmass spectrometryqPCR reagentsmolecular biology serviceslab servicesCROcontract research organizationDNA methylationChIP-seqATAC-seqwet-lab services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai Kangchen Bioengineering Co., Ltd. Comparables

Compare Shanghai Kangchen Bioengineering Co., Ltd. with similar companies based on industry and business-model similarity.

Shanghai Kangchen Bioengineering Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Shanghai Kangchen Bioengineering Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionJan 1, 2023
M&AJan 1, 2023
Series CSep 1, 2022
Series BAug 16, 2021
Series AMar 1, 2020

Shanghai Kangchen Bioengineering Co., Ltd. Investors

Notable investors and investment history

Shanghai Kangchen Bioengineering Co., Ltd. investors
InvestorRounds
鹊山资本Series B
Beijing Taikang Investment Management Co., Ltd.Series B
Longwater InvestmentSeries B
Shenzhen Capital GroupSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2023

    Completed a Series C Extension funding round.

  • Mar 1, 2020

    Raised Series A round with Shenzhen Capital Group

Shanghai Kangchen Bioengineering Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shanghai Kangchen Bioengineering Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shanghai Kangchen Bioengineering Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year FoundedN/A
Last FundingJan 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?